https://www.optimumcomms.com/wp-content/uploads/2023/10/HERVOLUTION_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-12-19 13:01:492023-12-19 13:01:49HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
https://www.optimumcomms.com/wp-content/uploads/2023/10/HERVOLUTION_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-12-19 13:01:492023-12-19 13:01:49HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer
Vicore continues to strengthen its leadership in idiopathic…

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron
• Further strengthening of leadership team following the appointment…

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury
Mission gains clearance from US FDA for Phase II trial of MTX562…

Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation
AP30663 achieved proof of mechanism with first-in-class SK channel…

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM
Collaboration with CSEM will speed up identification of suitable…

Biocomposites exceeds revenue expectations and takes a big step forward in its research and development collaboration with Swiss innovator CSEM
New record for sales growth and number of patients supported
…

Versameb Announces Publication in Molecular Therapy – Nucleic Acids Journal Demonstrating the Potential of Engineered IGF-I mRNA as a Regenerative Therapeutic
Basel, Switzerland, 12 December 2023: Versameb AG (“Versameb”),…

Astraveus appoints Dr. Lars Henrik Peeck as Chief Business Development Officer
Paris, France, 12 December 2023 – Astraveus SAS (“Astraveus”…

Poolbeg Pharma – POLB 001 Data Presented at ASH
11 December 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference
Data demonstrates METTL1 inhibition in vitro at low nanomolar…

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023
Updated safety and clinical efficacy data presented at leading…

Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)
Vesper Bio, backed by Lundbeckfonden BioCapital, initiates…

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
New deal builds on encouraging preliminary clinical data…

Ariceum Therapeutics announces granting of US and Canadian patents for its Gallium-68 radiopharmaceutical production kit
Berlin, Germany, 6 December 2023 – Ariceum Therapeutics, a…

Versameb AG Names Dr. Alexandre LeBeaut as Chair of the Board of Directors
Versameb AG (“Versameb”), a pre-clinical stage company focused…

Sofinnova Partners unveils Sofinnova.AI: A cutting-edge artificial intelligence platform set to transform its life sciences investment practice
Combination of real time scientific databases with proprietary…

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer
Experienced, innovative biotech and pharma leader with demonstrated…

Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson’s Disease
Company on-track to dose first participant in multi-part,…

The first six companies enter the Deep Tech Lab – Quantum start-up accelerator at BII to unlock the potential in quantum science
BioInnovation Institute (BII), an international non-profit foundation…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York